CytRx, Rodman & Renshaw Techvest Healthcare Conference, Massachusetts Biotechnology Council s Mass Opportunities, National Conference on Biotechnology Ventures, Qiagen, Knowledge Foundation, Biophysical Society | GenomeWeb

CytRx Exclusively Licenses Out Non-RNAi Assets to SynthRx

In line with its efforts to refocus entirely on RNAi, CytRx said this week that it has exclusively licensed Flocor, a phase III intravenous agent being developed for sickle cell disease treatment, as well as its OptiVax vaccine delivery technology and related anti-infective products, to SynthRx.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.